Extending Healthy Lifespan

Next Generation Therapies for Age-Related Diseases

Mission & Vision

At AION Healthspan, our mission is to extend human healthspan by developing innovative cellular therapies that prevent, delay, and reverse age-related diseases. We are committed to transforming the paradigm of healthcare from symptom management to addressing the root causes of chronic inflammatory conditions.

Learn More

About Us

AION Healthspan is pioneering breakthrough cellular therapies to prevent, reverse, and combat age-related degenerative conditions. Our innovative REJUVXL™ technology transforms how we approach chronic inflammatory diseases, focusing on early intervention for better health outcomes and extended quality of life.

Learn More

REJUVXL™: Transforming Chronic Kidney Disease Treatment

REJUVXL
REJUVXL

Our flagship program targets Chronic Kidney Disease (CKD), a condition affecting 38 million Americans including one-third of adults over 65. Unlike current treatments that merely slow disease progression, REJUVXL™ has the potential to stabilize or reverse kidney function decline.

Our Phase 1/2a clinical trial in CKD patients is set to begin in Q1 2025, with plans to expand to additional indications including acute lung conditions and diabetes. With promising preclinical and clinical evidence already demonstrating efficacy, REJUVXL™ represents a paradigm shift in treating age-related diseases.

TECHNOLOGY

Next-Gen Cell Therapy

DEVELOPMENT STAGE

Phase 1/2a Q1 2025

MARKET POTENTIAL

38M+ Patients
Read More